BioTheryX, Inc.

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
CDK4/6Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

May 2026PresentationBTX-9341Phase 1a dose-escalation data (NCT06515470) at ESMO Breast 2026: no dose-limiting toxicities

Financial reports

No financial reports recorded.